• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

经皮冠状动脉介入治疗后冠状动脉钙化和炎症对不良心血管事件风险的联合及独立影响:来自大型单中心注册研究的结果

Combined and independent impact of coronary artery calcification and inflammation on risk for adverse cardiovascular events after percutaneous coronary intervention: Results from a large single-center registry.

作者信息

Aoi Shunsuke, Baber Usman, Kovacic Jason C, Mehran Roxana, Aquino Melissa, Dangas George, Sweeny Joseph, Vijay Pooja, Shah Srushti, Barman Nitin, Moreno Pedro, Kini Annapoorna S, Sharma Samin K

机构信息

Department of Cardiology, Mount Sinai Beth Israel, New York, New York.

The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York.

出版信息

Catheter Cardiovasc Interv. 2020 Sep 1;96(3):E278-E286. doi: 10.1002/ccd.28784. Epub 2020 Feb 22.

DOI:10.1002/ccd.28784
PMID:32087000
Abstract

PURPOSE

Our study investigated the impact of coronary artery calcification (CAC) and systemic inflammation on risks for major adverse cardiovascular events (MACE) following percutaneous coronary intervention (PCI).

BACKGROUND

CAC and systemic inflammation are known to be associated with an increased risk of cardiovascular events.

METHODS

A total of 17,711 consecutive patients who underwent PCI in our hospital between January 1, 2009 and December 31, 2015 were categorized according to the degree of CAC (moderate/severe vs. none/mild) and high-sensitivity C-reactive protein (hsCRP) level (≥2 vs. <2 mg/L). MACE was defined as death, myocardial infarction (MI), or target vessel revascularization (TVR) occurring over 1 year.

RESULTS

Within the four groups, patients with both moderate/severe CAC and elevated hsCRP (n = 1,814 [10.2%]) were older with more comorbid risk factors compared to those with moderate/severe CAC alone (n = 1,687 [9.5%]), elevated hsCRP alone (n = 7,597 [42.9%]) or neither abnormality (n = 6,613 [37.3%]). The analogous 1-year MACE rates were 21.2, 14.9, 11.5, and 7.8%, respectively (p-trend < .001). Results were unchanged after multivariable adjustment, suggesting synergistic adverse effects in patients with both CAC and elevated hsCRP.

CONCLUSIONS

The presence of both moderate/severe CAC and systemic inflammation confers a synergistic effect on risk for MACE following PCI, indicating the need for novel or more intense therapeutic interventions to mitigate risk in such patients.

摘要

目的

我们的研究调查了冠状动脉钙化(CAC)和全身炎症对经皮冠状动脉介入治疗(PCI)后主要不良心血管事件(MACE)风险的影响。

背景

已知CAC和全身炎症与心血管事件风险增加有关。

方法

对2009年1月1日至2015年12月31日期间在我院连续接受PCI的17711例患者,根据CAC程度(中度/重度与无/轻度)和高敏C反应蛋白(hsCRP)水平(≥2与<2 mg/L)进行分类。MACE定义为1年内发生的死亡、心肌梗死(MI)或靶血管血运重建(TVR)。

结果

在四组中,与单独存在中度/重度CAC(n = 1687 [9.5%])、单独hsCRP升高(n = 7597 [42.9%])或无异常(n = 6613 [37.3%])的患者相比,同时存在中度/重度CAC和hsCRP升高的患者(n = 1814 [10.2%])年龄更大,合并的危险因素更多。类似的1年MACE发生率分别为21.2%、14.9%、11.5%和7.8%(p趋势<0.001)。多变量调整后结果不变,提示CAC和hsCRP升高的患者存在协同不良影响。

结论

中度/重度CAC和全身炎症同时存在对PCI后MACE风险具有协同作用,表明需要新的或更强化的治疗干预措施来降低此类患者的风险。

相似文献

1
Combined and independent impact of coronary artery calcification and inflammation on risk for adverse cardiovascular events after percutaneous coronary intervention: Results from a large single-center registry.经皮冠状动脉介入治疗后冠状动脉钙化和炎症对不良心血管事件风险的联合及独立影响:来自大型单中心注册研究的结果
Catheter Cardiovasc Interv. 2020 Sep 1;96(3):E278-E286. doi: 10.1002/ccd.28784. Epub 2020 Feb 22.
2
Correlates and Impact of Coronary Artery Calcifications in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration.经皮冠状动脉介入治疗(PCI)联合药物洗脱支架(DES)治疗女性患者中冠状动脉钙化的相关性及其影响:来自女性创新和药物洗脱支架(WIN-DES)合作研究。
JACC Cardiovasc Interv. 2016 Sep 26;9(18):1890-901. doi: 10.1016/j.jcin.2016.06.022.
3
Prevalence, correlates, and impact of coronary calcification on adverse events following PCI with newer-generation DES: Findings from a large multiethnic registry.新一代药物洗脱支架PCI术后冠状动脉钙化的患病率、相关因素及其对不良事件的影响:一项大型多民族注册研究的结果
Catheter Cardiovasc Interv. 2018 Apr 1;91(5):859-866. doi: 10.1002/ccd.27204. Epub 2017 Jul 19.
4
Coronary Calcification and Long-Term Outcomes According to Drug-Eluting Stent Generation.冠状动脉钙化与药物洗脱支架世代与长期预后。
JACC Cardiovasc Interv. 2020 Jun 22;13(12):1417-1428. doi: 10.1016/j.jcin.2020.03.053.
5
Outcomes of patients with myocardial infarction who underwent orbital atherectomy for severely calcified lesions.因严重钙化病变接受眼眶动脉粥样硬化切除术的心肌梗死患者的预后。
Cardiovasc Revasc Med. 2017 Oct-Nov;18(7):497-500. doi: 10.1016/j.carrev.2017.05.005. Epub 2017 May 7.
6
Residual Inflammatory Risk in Patients With Low LDL Cholesterol Levels Undergoing Percutaneous Coronary Intervention.经皮冠状动脉介入治疗患者的低 LDL 胆固醇水平下的残余炎症风险。
J Am Coll Cardiol. 2019 May 21;73(19):2401-2409. doi: 10.1016/j.jacc.2019.01.077.
7
Orbital Atherectomy for the Treatment of Long (≥25-40 mm) Severely Calcified Coronary Lesions: ORBIT II Sub-Analysis.用于治疗长(≥25 - 40毫米)严重钙化冠状动脉病变的轨道旋切术:ORBIT II亚组分析
Cardiovasc Revasc Med. 2020 Feb;21(2):164-170. doi: 10.1016/j.carrev.2019.12.027. Epub 2019 Dec 28.
8
Orbital atherectomy for treating de novo, severely calcified coronary lesions: 3-year results of the pivotal ORBIT II trial.用于治疗初发、严重钙化冠状动脉病变的轨道旋切术:关键的ORBIT II试验3年结果
Cardiovasc Revasc Med. 2017 Jun;18(4):261-264. doi: 10.1016/j.carrev.2017.01.011. Epub 2017 Jan 23.
9
Prognostic Value of Coronary Artery Calcium Scoring in Addition to Single-Photon Emission Computed Tomographic Myocardial Perfusion Imaging in Symptomatic Patients.有症状患者中,除单光子发射计算机断层扫描心肌灌注成像外,冠状动脉钙化评分的预后价值
Circ Cardiovasc Imaging. 2016 May;9(5). doi: 10.1161/CIRCIMAGING.115.003966.
10
Outcomes after Atherectomy Treatment of Severely Calcified Coronary Bifurcation Lesions: A Single Center Experience.严重钙化冠状动脉分叉病变旋切术治疗后的结果:单中心经验
Cardiovasc Revasc Med. 2019 Jul;20(7):569-572. doi: 10.1016/j.carrev.2018.08.017. Epub 2018 Aug 23.

引用本文的文献

1
Exosomal circ-0020887 and circ-0009590 as novel biomarkers for the diagnosis and prediction of short-term adverse cardiovascular outcomes in STEMI patients.外泌体circ-0020887和circ-0009590作为ST段抬高型心肌梗死患者短期不良心血管结局诊断和预测的新型生物标志物。
Open Med (Wars). 2023 Oct 11;18(1):20230807. doi: 10.1515/med-2023-0807. eCollection 2023.